摘要:
The present disclosure is directed to Compound I and Compound II as well as pharmaceutical compositions including Compound I or Compound II, or mixtures thereof. The disclosure is additionally directed to methods of making the aforementioned compounds and pharmaceutical compositions as well as their methods of use.
摘要:
The present invention relates to new cyclopropyl dihydrobenzofuran modulators of melatonin receptors, pharmaceutical compositions thereof, and methods of use thereof.
摘要:
Methods for treating abnormal muscular activity are disclosed. The methods may be performed remotely and permit monitoring of a subject outside a healthcare provider's office.
摘要:
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof represented by structural Formula I.
摘要:
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
摘要:
The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.
摘要:
The present invention relates to new aminothiazole modulators of beta- 3- adrenoreceptor activity, pharmaceutical compositions thereof, and methods of use thereof. Formula I
摘要:
The present invention relates to new napthylene inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof.
摘要:
The present invention relates to new 1-methylpyrazole modulators of substance P release, calcitonin gene-related peptide activity, adrenergic receptor activity, and/or 5 -HT receptor activity, pharmaceutical compositions thereof, and methods of use thereof.